AMGN
AMGEN INC
Key Financials
Revenue
$36.8B
↑ 10.0%
Net Income
$7.7B
↑ 88.5%
Gross Profit
$4.7B
↑ 4.3%
EPS (Diluted)
$14.23
↑ 88.2%
Operating Income
$9.1B
↑ 25.1%
Total Assets
$90.6B
↓ 1.4%
Cash & Equivalents
$9.1B
↓ 23.8%
Shareholders' Equity
$8.7B
↑ 47.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEFA14A | 4/15/2026 | View on SEC |
| DEFA14A | 4/7/2026 | View on SEC |
| DEF 14A | 4/7/2026 | View on SEC |
| ARS | 3/31/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AMGN |
| Company Name | AMGEN INC |
| CIK | 318154 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (805)447-1000 |